IRIS data- 86 Percent of Patients With Ph+ CML alive after 7 years

Press Release Source: Novartis Pharmaceuticals UK Ltd Data Shows Longest Ever Survival for Patients With Life-Threatening Leukaemia Treated With Breakthrough Treatment Monday December 8, 5:00 pm ET - 86 Percent of Patients With Ph+ Chronic Myeloid Leukaemia Treated With Breakthrough Treatment Glivec(R) are Alive After Seven Years(1) - Treatment Shown to Slow Disease Progression: Only one Patient out of 317 Experienced Disease Progression Between Year Six and Seven of Treatment(1) - Data Demonstrate Longest Overall Survival Observed to Date in This Disease Area ....read full press release here